This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical study was based on the intention to treat principle. The primary health outcomes studied included forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), peak expiratory flow (PEF), the provocative dose of histamine required to cause a 15% fall in FEV1 (PD15) expressed as geometric means and as dose steps. At analysis, groups were shown to be comparable in terms of sex, age, atopy, smoking habits, FVC, FEV1, PEF, health-related quality of life and treatment.
Effectiveness results
All effectiveness measures indicated a significant improvement in the intervention group during the treatment (p<0.001 except in FEV%, p<0.05). No significant changes were noted in the control group, except for PEF (p<0.01) and PD15 expressed as dose steps (p<0.001) which were significantly higher after one year. With respect to the difference between the group at one year, all outcome variables were higher in the intervention group: FVC (99.8 versus 94.7, p=0.08), FEV1 (92.3 versus 84.7, p=0.02), FEV% (91.9 versus 88.9, p=0.18), PEF (91.6 versus 87.1, p=0.17), PD15 expressed as geometric mean (0.31 versus 0.25, p=0.56), and PD15 expressed as dose steps (1.41 versus 1.23, p=0.28).
Clinical conclusions
At 1 year, the intervention group showed a better result than the control group in all outcome variables, but statistically the groups differed significantly from each other only in FEV1.
Modelling
No modelling was used.
Measure of benefits used in the economic analysis
The measure of benefits used was health-related quality of life (HRQOL) measured by the disease specific St George's Respiratory Questionnaire (SGRQ) and the generic 15D.
Direct costs
The costs were not discounted given the short time frame of the study (1 year). Quantities and costs were not reported separately. The direct cost estimate included the cost of a visit to the lung clinic, the cost of an inpatient day, the cost of a visit to the emergency clinic, drug costs, nursing costs and transportation costs. The quantity/cost boundary adopted was that of the hospital. The estimation of quantities and costs was based on actual data. The source of the cost data was the South Karelia Central Hospital. The price year was 1993.
Statistical analysis of costs
The Mann-Whitney test was carried out as appropriate.
Indirect Costs
The costs were not discounted given the short time frame of the study (1 year). Quantities and costs were not reported separately. All sickness days, the time required for intervention visits including time used for travelling and the average time spent on extra health care visits were recorded for the calculation of indirect costs. The quantity/cost boundary adopted was that of the patient. The estimation of quantities and costs was based on actual data. The source of the cost data was the South Karelia Central Hospital. The price year was 1993.
